{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:48:52Z","timestamp":1791254932330,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1097\/mpa.0b013e318164548a","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T21:01:03Z","timestamp":1236286863000},"page":"145-150","source":"Crossref","is-referenced-by-count":54,"title":["Serum Vascular Endothelial Growth Factor\/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer"],"prefix":"10.1097","volume":"37","author":[{"given":"Yu-Ting","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Nien","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Shiow","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jau-Min","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210212","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2036.2006.02961.x","article-title":"The epidemiology of pancreatic cancer in the United States: changes below the surface.","volume":"24","author":"Shaib","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R2-5-20210212","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic cancer.","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"key":"R3-5-20210212","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1517\/13543784.15.11.1395","article-title":"Pancreatic cancer: a review of recent advances.","volume":"15","author":"Eckel","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R4-5-20210212","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005.","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R5-5-20210212","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease.","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"R6-5-20210212","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1158\/1535-7163.MCT-06-0004","article-title":"Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.","volume":"5","author":"Giovannetti","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"R7-5-20210212","first-page":"CD002093","article-title":"Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.","volume":"3","author":"Yip","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-5-20210212","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ctrv.2006.12.003","article-title":"Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.","volume":"33","author":"Zalatnai","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R9-5-20210212","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1074\/jbc.271.2.603","article-title":"Vascular endothelial growth factor, a potent and selective angiogenic agent.","volume":"271","author":"Thomas","year":"1996","journal-title":"J Biol Chem"},{"key":"R10-5-20210212","first-page":"25","article-title":"Implication of vascular endothelial growth factor in the development and metastasis of human cancers.","volume":"12","author":"Arii","year":"1999","journal-title":"Hum Cell"},{"key":"R11-5-20210212","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V","article-title":"High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.","volume":"88","author":"Seo","year":"2000","journal-title":"Cancer"},{"key":"R12-5-20210212","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006676-200208000-00002","article-title":"High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.","volume":"25","author":"Niedergethmann","year":"2002","journal-title":"Pancreas"},{"key":"R13-5-20210212","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","article-title":"The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.","volume":"266","author":"Tischer","year":"1991","journal-title":"J Biol Chem"},{"key":"R14-5-20210212","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1476-4598-2-12","article-title":"Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer.","volume":"2","author":"Duffy","year":"2003","journal-title":"Mol Cancer"},{"key":"R15-5-20210212","first-page":"203","article-title":"Regulation of angiogenesis via vascular endothelial growth factor receptors.","volume":"60","author":"Veikkola","year":"2000","journal-title":"Cancer Res"},{"key":"R16-5-20210212","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00006676-200305000-00006","article-title":"Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival.","volume":"26","author":"Kuwahara","year":"2003","journal-title":"Pancreas"},{"key":"R17-5-20210212","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/01.mpa.0000166999.11889.2f","article-title":"Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival.","volume":"31","author":"Kobayashi","year":"2005","journal-title":"Pancreas"},{"key":"R18-5-20210212","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3835(03)00047-8","article-title":"Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis.","volume":"194","author":"Karayiannakis","year":"2003","journal-title":"Cancer Lett"},{"key":"R19-5-20210212","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0959-8049(97)10068-5","article-title":"Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma.","volume":"34","author":"Ellis","year":"1998","journal-title":"Eur J Cancer"},{"key":"R20-5-20210212","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0959-8049(98)00069-0","article-title":"Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.","volume":"34","author":"Fujimoto","year":"1998","journal-title":"Eur J Cancer"},{"key":"R21-5-20210212","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/1097-0142(20011001)92:7<1788::AID-CNCR1695>3.0.CO;2-Z","article-title":"Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival.","volume":"92","author":"Fujioka","year":"2001","journal-title":"Cancer"},{"key":"R22-5-20210212","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.ejca.2005.07.022","article-title":"Placenta growth factor is over-expressed and has prognostic value in human breast cancer.","volume":"41","author":"Parr","year":"2005","journal-title":"Eur J Cancer"},{"key":"R23-5-20210212","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/gut.2004.050831","article-title":"Placenta growth factor expression is correlated with survival of patients with colorectal cancer.","volume":"54","author":"Wei","year":"2005","journal-title":"Gut"},{"key":"R24-5-20210212","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling-in control of vascular function.","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R25-5-20210212","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/labinvest.3780050","article-title":"Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids.","volume":"80","author":"Hornig","year":"2000","journal-title":"Lab Invest"},{"key":"R26-5-20210212","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/bbrc.1996.1355","article-title":"Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.","volume":"226","author":"Kendall","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"R27-5-20210212","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1012245307884","article-title":"Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors.","volume":"4","author":"Barleon","year":"2001","journal-title":"Angiogenesis"},{"key":"R28-5-20210212","doi-asserted-by":"crossref","first-page":"E108","DOI":"10.1161\/01.CIR.102.15.e108","article-title":"sFlt-1, a potential antagonist for exogenous VEGF.","volume":"102","author":"Belgore","year":"2000","journal-title":"Circulation"},{"key":"R29-5-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006676-200208000-00001","article-title":"Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.","volume":"25","author":"Hoshida","year":"2002","journal-title":"Pancreas"},{"key":"R30-5-20210212","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.20613","article-title":"Combined endostatin\/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC.","volume":"41","author":"Graepler","year":"2005","journal-title":"Hepatology"},{"key":"R31-5-20210212","first-page":"2057","article-title":"Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.","volume":"7","author":"Mahasreshti","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R32-5-20210212","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.clinbiochem.2004.03.012","article-title":"Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types.","volume":"37","author":"Ilhan","year":"2004","journal-title":"Clin Biochem"},{"issue":"1-2","key":"R33-5-20210212","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2006.01.022","article-title":"The ratio of membrane-bound form Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer.","author":"Takenaka","year":"2007","journal-title":"Cancer Lett"},{"key":"R34-5-20210212","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1542\/peds.2004-2240","article-title":"Excess soluble fms-like tyrosine kinase 1 and low platelet counts in premature neonates of preeclamptic mothers.","volume":"116","author":"Tsao","year":"2005","journal-title":"Pediatrics"},{"key":"R35-5-20210212","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.ejca.2005.04.044","article-title":"Molecular prognostic markers in pancreatic cancer: a systematic review.","volume":"41","author":"Garcea","year":"2005","journal-title":"Eur J Cancer"},{"key":"R36-5-20210212","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.1079562","article-title":"Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.","volume":"299","author":"LeCouter","year":"2003","journal-title":"Science"},{"key":"R37-5-20210212","doi-asserted-by":"crossref","first-page":"9349","DOI":"10.1073\/pnas.95.16.9349","article-title":"Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.","volume":"95","author":"Hiratsuka","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R38-5-20210212","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0002-9440(10)63965-X","article-title":"Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells.","volume":"158","author":"Dunk","year":"2001","journal-title":"Am J Pathol"},{"key":"R39-5-20210212","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1535-6108(02)00028-4","article-title":"Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1\/VEGF heterodimers.","volume":"1","author":"Eriksson","year":"2002","journal-title":"Cancer Cell"},{"key":"R40-5-20210212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.10121","article-title":"Significance of vascular endothelial growth factor (VEGF)\/soluble VEGF receptor-1 relationship in breast cancer.","volume":"98","author":"Toi","year":"2002","journal-title":"Int J Cancer"},{"key":"R41-5-20210212","first-page":"1399","article-title":"Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.","volume":"9","author":"Lamszus","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R42-5-20210212","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1349-7006.2007.00402.x","article-title":"Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis.","volume":"98","author":"Yamaguchi","year":"2007","journal-title":"Cancer Sci"},{"key":"R43-5-20210212","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ymthe.2004.12.015","article-title":"Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.","volume":"11","author":"Zhang","year":"2005","journal-title":"Mol Ther"},{"key":"R44-5-20210212","first-page":"2019","article-title":"Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.","volume":"62","author":"Hasumi","year":"2002","journal-title":"Cancer Res"},{"key":"R45-5-20210212","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.2001.19.4.1207","article-title":"Clinical implications of circulating angiogenic factors in cancer patients.","volume":"19","author":"Poon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R46-5-20210212","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia.","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"R47-5-20210212","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"key":"R48-5-20210212","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/cncr.20187","article-title":"Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.","volume":"100","author":"Hu","year":"2004","journal-title":"Cancer"},{"key":"R49-5-20210212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF02484513","article-title":"Angiogenesis and antiangiogenic therapy for malignant gliomas.","volume":"21","author":"Takano","year":"2004","journal-title":"Brain Tumor Pathol"},{"key":"R50-5-20210212","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6602374","article-title":"Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.","volume":"92","author":"Bando","year":"2005","journal-title":"Br J Cancer"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006676-200808000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:51:36Z","timestamp":1618037496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-200808000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e318164548a","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}